Вы находитесь на странице: 1из 75



2003 .


..

.. , .. ,
..

.. , .. ,
..

.. , .. ,
..

..

..

reklama_pf@geotar.ru

podpiska_pf@geotar.ru

119991, ,
:, . 2/62
(495) 967:15:66
(495) 935:64:00
:mail: pedpharm@nczd.ru


:
119828, . ,
. . ,1
./: (495) 101:39:07
www.geotar.ru


.. ()
.. ()
.. ()
.. ()
.. ()
.. ()
.. ()
.. ()
.. ()
.. ()
.. ()
.. ( )
.. (:)
.. ()
.. ()
.. ()
.. (:)
.. ()
.. ()
.. ()
.. ()
.. ()
.. ()
.. (:)
.. ()
.. ()

.. ()
.. ()
.. ()
.. ( )
.. ()
.. ()
.. (:)
.. ()
.. ()
.. (, )
.. ()
.. ()
.. ()
.. ()
.. ()
.. ()
.. (:)
.. ()
.. ()
.. ()
.. ()
.. ()
.. (:)
.. ()
.. ()
.. ()


:
, :
:
11.03.2002 .
15.12.2005 .
77:22768.

.

.

,
141400 ., . , .
,2.
5000

18100
18101


.

1
/ 1/ 2006

Pediatric
pharmacology
The Union of Pediatricians of Russia Scientific Practical Journal
Published since 2003
Issued once in two months

Editorinchief
L.S. Namazova
Deputy editorsinchief
J.Iu. Gorelova, O.V. Chumakova,
L.P. Mazitova
Research editors
E.V. Antonova, A.G. Timofeeva,
T.I. Haibullin
Secretariesgeneral
J.G. Levina, A.G. Surkov,
R.M.Torshkhoeva
Art director
A.B. Arkhutik
Publishing editor
U.G. Pugacheva
Advertising department
reklama_pf@geotar.ru
Sales department
podpiska_pf@geotar.ru
Correspondence address
2/62, Lomonosov avenue,
Moscow, 119991
e:mail: pedpharm@nczd.ru

Publishing group
GEOTAR:Media
1a, M. Pirogovskaya street, Moscow,
119991
tel./fax: (495) 101:39:07
www.geotar.ru

Editorial board
E.I. Alekseeva (Moscow)
N.G. Astafieva (Samara)
E.N. Baibarina (Moscow)
I.I. Balabolkin (Moscow)
A.A. Baranov (Moscow)
Iu.B. Belousov (Moscow)
B.M. Blokhin (Moscow)
M.R. Bogomilsky (Moscow)
T.E. Borovik (Moscow)
V.V. Botvinieva (Moscow)
G.N. Buslaeva (Moscow)
A.I. Volkov (Nizhniy Novgorod)
I.M. Vorontsov (St.Petersburg)
A.V. Gorelov (Moscow)
A.L. Zaplatnikov (Moscow)
A.A. Efimova (Moscow)
V.V. Ivanova (St.Petersburg)
I.I. Ilyina (Moscow)
L.F. Kaznacheeva (Novosibirsk)
E.V. Karpukhin (Kazan)
R.A. Keshishian (Moscow)
I.Ya. Kon (Moscow)
N.A. Korovina (Moscow)
D.S. Korostovtsev (St.Petersburg)
N.G. Korotky (Moscow)
A.A. Korsunsky (Moscow)

Mass media registration certificate


dated December 15 2005.
Series 77:22768 Federal
service for surveillance over non:viola:
tion of the legislation in the sphere of
mass communications and protection
of cultural heritage.
Editorial office takes no responsibility
for the contents of advertising material.
No part of this issue may be reproduced
without permission from the publisher.

L.M. Kuzenkova (Moscow)


K.S. Ladodo (Moscow)
T.V. Latuisheva (Moscow)
S.E. Lukhushkina (Nizhniy Novgorod)
J.M. Lutsky (Moscow)
G.A. Lyiskina (Moscow)
I.V. Makarova (St.Petersburg)
S.V. Maltsev (Kazan)
O.I. Maslova (Moscow)
A.A. Namazova (Baku, Azerbaijan)
L.M. Ogorodova (Tomsk)
O.I. Pikuza (Kazan)
A.S. Potapov (Moscow)
A.G. Rumiantsev (Moscow)
G.A. Samsyigina (Moscow)
E.V. Sereda (Moscow)
A.S. Simakhodsky (St.Petersburg)
G.I. Smirnova (Moscow)
P.A. Tatarinov (Moscow)
V.K. Tatochenko (Moscow)
E.V. Uvarova (Moscow)
A.N. Tsoy (Moscow)
N.P. Shabalov (St.Petersburg)
R.R. Shilyaev (Ivanovo)
M.Iu. Scherbakova (Moscow)
G.V. Yatsyik (Moscow)

While reprinting publications one must


make reference to the journal
Pediatric pharmacology
Printed in the printing:office
Moment, 2, Nakhimov street,
Khimki, Moscow region, 141400.
Edition 5000 copies.
Subscription indices are in catalogue
Rospechat
For natural persons 18100
For juridical persons 18101

3
/ 1/ 2006

Founder
The Union of Pediatricians of Russia

, !

,
, ,
 ,
,

/ 1/ 2006

5
.
, . :,
, , ,
, ,
,
.
, :
, .
.
,
.
,
,
, . ,
, . ,
. , ..
,
. ,
.
, .
, !
, ,
, , ,
. .

.. ,
,


:
,
, .
: 119991, , , 2/62, . (495) 134:70:01

, ,

. :
,
, :
,
, :
.

. ,
.
,
, , :
, , , ..


,
.
, :
, ,
. ,
:
? ::
, :

. .
::
. :
:
, , , ,
,

. ?
, ,
, :
, :
,
. :
:
.
.
,
:
:
, :

? ,
.
, :
.


, :
5 . :
40 000 2 :
.
, :
, ,
19 . :
, : 1
(,
).
, , :
:
:
,
:
. ? :
,
,
, ,
, , .

( ,
,
,
, :
). ,
:
. , :
:
, (
, , , :
)
. , :
( :
, D)
.
,
,
,
.



:
. ,
:
. , ,
,
2004 . ,
(
, , , .).
:
:
, (
)
(
) :
, .
, :
:
,
,
:
.
:
:
.
(
).
,
.
2 , :
,
. ,

,
?

, :
, :
, :
. :
, :
, , :
. :
(), :
(:
),
:
, ,
, :
.
:

: :
.

. :

:
,
, :
. , ,
:5 ,

. ,
, .
, :
, , , :
: . :,
:
. ,


, , , .
, :
:
, , , :
:
!.
, :
, .
,
, ,
.
, :
, .
:
/ :
/
.
.
,
. :, :
, :
, 4 . :,

. : :

.
:
, .
:
.

.
,

. :
! , ,
. , :
,
:
, .

7
/ 1/ 2006


, :

, , :
.
,
, 2005 .

, , :
,
, , :
, , .
,
, :

, ,
, .
. :
:
:
() . :
,
:
/ , :
.
,
/

. , :
:
/ , :
, :
?
. , :
, :
:
, , :
,
:
, .
.
, ,
, .
.
, :
:
, .
,
, , :
. :
.
2
.

1982 . :
, 2004 .
, ,

.

, , :
:
.
,

/:

/ .
,
:
.
,
() .
:

. , 1999 .
26 454 975
6 055 029 .
2000 . 12%
[1].
.
( 1,3 , 1,4
), 2,3 ,
. ,
,

. .
, ,
. , ,
, ,

. , :
03 .
. :

(Acute medical Emergency Nursing
guide), :
,
[2].
,
, :
. :
, ,
.
:
,
, : ,

, :
, ,
, :

. ,
,
,
(, ).
:
. , ..
, :

50 ,
1,32%,
.
,
( :
, ), ,
,

,
:
:
, ,
. :
.
.

, :

:
2:3 0 (!).
10 .
.
>80% :
.


> 1,3 .
, ,

, .
, .
? !
.. (2000), :
2 [7]:
1. ,
;
2. ,
.*

(%)

20:30%

40:50%

50%

70%

80%

20:40%

20:50%

* .. , , 2001 .

9
/ 1/ 2006

,
.

:
, :

.

,

. , :
: :
, , :
. ::
:
:
[3], ,
, :
:
(
, :

: , :
, .,
), (:
, :
).
.. [4], :

19,2
. . .. :
, , :

26,2 .,
,
, 42 .; 6,4
,
, 1

1,5 ., 5,5 . :

. , A.K. Grove et al., (1996), :

:
, , :
, :
, :
[5]. . K. Banz et al. (1994)

, 1
:

49,5 310 $ [6].
,
: , ,
:
.
.
:
. . , :

,
().
:
.
,
: . : :

, .
, ,
:
?. ,

, , :

.
, ,

,
.
, :
.

.


1. .., .., .., ..
: ,
//
. .. 2002. . 224.
2. Acute medical Emergency Nursing guide. // 2001. P. 13.
3. :
/ : . . 2002 73 .
4. .., .., .. .

19

// . 2001. 4. . 62:64.
5. Grove A.K., Bergemann R., Keller R. Preventive treatment of chronic
bronchitis: a cost:effectiveness analysis for an immunoactive bacterial
extract in Switzerland // Brit. J. Med. Econom. 1996. V.10. P. 1:14.

6. Banz K., Schwicker D., Tomas A.M. Economic evaluation of immu:


noprophylaxis in children with recurrent ear, nose and throat infec:
tions // PharmacoEconomics. 1994. V. 6(5). P. 464:477.
7. .. .
. 2000.
8. Kumar S. Drug linked to child death is still available in India. BMJ.
2003. V. 326. P. 70.
9. Kunal Saha. Use of nimesulidein Indian children must be
stopped.// BMJ. 2003. V. 326. P. 713
10. Merlani G., Fox M., Oehen H.P. et al. Fatal hepatotoxicity secondary
to nimesulide. //Eur. J Clin Pharmacol. 2001. V. 57. P. 321:326.
11. Singhal K.C., Rahman S.Z. Nimesulide induced hepatitis in a
child of 5 years. A case report. www.medbeats.com/nimesulidein:
ducedhepatitis.htm.

10


:
, 3:4 2005 .,
www.geotar.ru .

!
,
2006 .
: :,
, , ,
, .

,
.

12



, ,
, ..

reklama:vsp@geotar.ru

podpiska:vsp@geotar.ru

119991, , , . 2/62
e:mail: vsp@nczd.ru


:
..., ..

reklama:pf@geotar.ru

podpiska:pf@geotar.ru
:
119991, , , . 2/62
e:mail pedpharm@nczd.ru


, .
, ,
.

.. 1, .. 1, .. 2, .. 1, .. 3
,
, ,
3

:



. , ,
, , ,
,
.
: , , .
(), .. ..
, () 4 ( :
), 5 ( : ) 6 (
) [1]. ::
, , :
: , 90% :
[2]. ,
. ,
,
[3].
, , ,
: :
: (2002) [4].
2 :
:
( : ; ,
; Th2: )
,
:
(
; :
; , , :
; ;
: ).
:
,  , , .
, , ,
, ,
. , , :

R.M. Torshkhojeva1, , V.V. Botvinjeva1, T.G. TagiZade2,


L.S. Namazova1, T.E. Taranushenko3
1Scientific Center of Childrens Health, Russian Academy
of Medical Sciences, Moscow, Russia
2Azerbaijan State Medical University, Baku, Azerbaijan
3Krasnoyarsk State Medical Academy, Krasnoyarsk, Russia

hildren of megapolises who


fall ill frequently:
acute respiratory infection
prevention and treatment

THE ARTICLE IS DEVOTED TO PREVENTION AND TREATMENT OF ACUTE


RESPIRATORY DISEASES CHILDREN OF MEGAPOLISES WHO FALL ILL
FREQUENTLY. THE AUTHORS PROVE THE THESIS THAT CHILDREN FALLING
ILL FREQUENTLY AND RESIDING IN MEGA CITIES, AND NOT ONLY IN RUSSIA,
HAVE A SIMILAR IMMUNE STATUS, ACCORDING TO WHICH NOT ONLY
THERAPEUTIC BUT ALSO PREVENTIVE IMMUNOMODULATORY TREATMENT
COURSES MUST BE ADMINISTERED TO THEM.
KEY WORDS: FREQUENTLY ILL CHILDREN, BACTERIAL
IMMUNOMODULATION, CYTOKINIC STATUS.

13
/ 1/ 2006

:
,
,



: 119991, ,
, 2/62,
. (495) 134:03:92

14

( :
) (
) :

.
,
. :
.
: ,
:
, ,
.

,
. :
:
, ,
:
, .,
,

23 . :

: (:) .

,
, :
, :
618 .
: IgM
, IgG IgA
, 2 5 .
IgM
1 , IgG
60%, IgA 20%
. IgG1 IgG3
8 , IgG2 IgG4 1012 .
IgE .
CD4/CD8 3; :

, .. , , :
, :
.
h2 ( T:
2: ): : (CD4+:), :
, :
10 ,
, :2 (
1:
). , :4 :5, :
2: ( ),
, .
,

Th1 
2 ( 2). T::
2: 6 ,
2
56 .
, Th2:
,
:
(..
).

, :

: . ,
:
,
(, , :
), (, 2
, , ). :
,
:
. :
,
.
:
, ,
. :

,
. , 1997 2001 . :
:
1,7 , :
1,5 . ,
:
, , ,
, Fe, F, Ca, Se, I.
:
.
:
, :
, :
, , :
[5].
:
, , :
, :
, :

[6].
, , :
, :

2: , .
, :
IgE (,
, , ) :
50% [7].

30%, 10%,
40% [8].

:
:
. ,
, ,
:
.
. ,
,
, :
, :
( .). ,
( ,
), ,

, :
[9].
, :
, :

, . :
:

.
,
, ,
(

). :
( 19 ) :
.
.

, ,
. , ,
140 . (!) :
, .
, :

,
. :

:
(
:). :
:
. ,
:
.
, :
180
6 14 . :
3 : , :
; ;
. 60 .

:
:
.
, , :
.
.
:
,
.
. 1, :
(20%) (80%)
.
,

.
. 1, :
2 (
, .. ), 4, IgE
.

.

. 2.
, ,


, 4,
8 .

:
.

15
/ 1/ 2006

,
, ,
. :
:,

, .. :
, :
;
:
. :
,
:
[10].
, :
, 
, 
,
,
. :
, :
, : .
20012004 . :
, . :
:
() ().
:
3 : (:
), ()
().
. :
(), (); ,

8 : 1 ().

,
.
, :
. , 3040
,
1520 :
: , , , .

( , , 1, 6, ).
, :
, :
:
.
, ,

, 
, 

. , :
:

.
:
.


2 .
, , :
,
1 :
:
(, 19, ),
, ,

. 1.
.

16

,
, (,
, )
:
19
.
2 ( 60 )
:
() :
( :
, );
19

19. :
1
5 , :
2 .
20 (
), , :
.
.
:
, : :
, : :
,
.
,
19
: :

.
, . :
:
, / :
.
, 19 , :
:
19,
1.


()


()


()

48

49

48

12

11

12

: n = 180

60

60

60

. 2.
.

2.

19

: n = 120

n = 60

n = 60

2,8

4,7

()

4,1

8,9

2,5

9,5


()

0,2

2,3

(
):
3 ; 2 ; 1 .
. 3. 6 ,
19 ( 19)
().

. 4. .

4
8. , :
, 8 4 :
, . ,
19, (. 3), :
(. 4). :
4 .

1. .., .. . ::
. . , 1986. 45 .
2. ..
//
2004. 3(4) . 1124.
3. Acute Medical Emergency Nursing Guide 2001. P. 98.
4. : :
. :
., 2002. 73 .
5. .., .., ..
// :
. / . .. , .. . .: :
, 1998. . 24772.
6. ..

(. 2).
, :
19,

, :
.

.
// :
. ., 1990. . 701.
7. .., .. . //
. 2002. 10(3). . 1257.
8. .. : :
: . . ... . .
. ., 1987.
9. .., .. :
. .: , 1981.
10. .., .., .. :
. ,
1998. 135 .

/ 1/ 2006

17




""

Neonatal Pharmacology

V EAACI Congress in Vienna 2006


5

2006 .

8 2006 .

()
: 117105,
, . ,
., .4, .3
/:
+7 (495) 975:08:46
();
+7 (495) 510:98:51;
+7 (495) 510:98:52;
www.pl:assembly.org;
Email: info@pl:assembly.org

1820 2006 .
,
: Registrar, 11900
Silvergate Drive, Dublin, CA 94568
: 925:828:7100, ext 3
: 800:329:9923
E:Mail: info@cforums.com

1014 2006 .
,
: Executive Office Sweden,
Executive Manager, C. OSTROM P.O.
Box 24140, S:104 51 STOCKHOLM,
SWEDEN
: 46:84:596:623
: 46:86:633:815
E:Mail: executive.office@eaaci.org

.. , .. , ..
,

,

,
, :
. :
,
, :
, , , .
: , , , , .

:
,

;
119991, ,
: , 2/62,
. (495) 134:03:92

18

:
().
,
412%.
510% [1].
( 70%) , , :
[2], , , :
.
(
) .
, , , :
,
:
.
, ,
[3], :
. ,
65% , ,
, :
[4, 5].
, , :
, , [6:9]. ,
. , ,
[10],
[11]. :
. :
, ,
,
(NREM) [12:14]. C.
Janson et al. , , ,

[8].

. , ,
,
.

K.E. Efendieva, O.V. Liubshina, M.V. Vigant


Scientific Center of Childrens Health, Russian Academy of
Medical Sciences, Moscow

Sleep disturbance and its cor


rection in the children suffer
ing from bronchial asthma

THE STUDY DEMONSTRATES THAT UNCONTROLLED BRONCHIAL ASTHMA


WITH PERSISTENT NOCTURNAL SYMPTOMS MAY LEAD TO SLEEP STRUC:
TURE DISTURBANCE, MAKING IT LESS EFFECTIVE. AN ADEQUATE ANTIIN:
FLAMMATORY THERAPY USING STATE:OF:THE:ART MEDICINAL MEANS
HELPS TO CONTROL THE DISEASE, ARREST NOCTURNAL SYMPTOMS,
RESULTING IN SLEEP STRUCTURE RESTORATION AND THE IMPROVEMENT
OF ITS QUALITY THUS IMPROVING LIFE QUALITY OF PATIENTS AS WELL AS
THEIR PARENTS.
KEY WORDS: BRONCHIAL ASTHMA, SLEEP DISTURBANCE,
POLYSOMNOGRAPHY, FLUTIKAZON, SALMETEROL.

(90,86,5%) (6,51,2 )
S. Uliel et al. [21].
:
, , :
. ,
:
[24, 25], :
,
[26, 27] :


. .. , :


[28]. , L. Wiegand et al., :
, :

[29].
, ,

, , :
. :

.

, :
, 20
6 18 ,
, :
.
. 1.
, :
4
,
16,32,22,
(12,051,98). 2::

4,50,47 .
1 (1)
72,74,86%, 24,93,25%.

( ,
, , :
, :
, ), :
( ,
, :
IgE) (:
IgG, IgM, IgA ).
( :

SCHLAFLABOR:II, SAGURA
Medizintechik Gmbh, )
81.

(
) ,
, :
(NREM) ,
, ,
(REM) :
( 14,026,45%
2025% [19]).

19
/ 1/ 2006

A. Kales et al. , :
[15],
,
[16].
, , :
. :
, :
,
()
50%. :
, , :
.
,
,
.
, ,
, 59% :
, 51% :
.
, 34%
1 :
, , 5% :
[17].
G. Stores et al.
, , , ,
, :
(NREM REM) ,
:
, , :
. ,
:
() [18].

:

. :
:
:
. :
(,
), :
:
. , :
,
.
:
,
:
. :
:
, , ,
:
.
.. , :
, ,
: I 2:5%, II : 45:55%,
: 13:23%, : 20:25% [19].
,
50 70 ,
:
92% [20, 21]. F. Chipps et al.
, ,

[22].
/, M. Witmans et al. [23],
1,5 2 ; :

1.
(/), . (%)

2.

13 (65)/7 (35)

17,2013,38

13,96,8

6:7 , . (%)

4 (20)

454,0749,8

482,4776,46

8:9 , . (%)

3 (15)

, %

80,782,62

94,102,47*

10:12 , . (%)

3 (15)

, %

7,14,67

3,82,44*

13:15 , . (%)

8 (40)

I , %

0,30,15

0,270,18

16:17 , . (%)

2 (10)

II , %

45,6010,75

44,5114,1

III , %

8,61,58

7,392,93

20

, . (%)

10 (50)

IV , %

18,496,06

16,068,01

, . (%)

10 (50)

REM, %

14,026,45

22,066,23*

5,43,5

:,

25,94,83

16,710,26*

, . (%)

14 (70)

0,80,2

0,160,03

IgE, /

368,5 (85; 675)


, %

94,270,88

94,930,59

, . (%)

17 (85)

, :

* p<0,05 .

:
25,94,83 .
:
. :
7,14,67%. ,

80,782,62% ( 90,86,5% [21]).
. 2, /,
/ 1 (:
1,52 [23]),

(
92% [20, 21]) :
. :

.
, , :


, .
:
:
+ ,
.
3

(
, , :
2: ,
1 92,54,24,
2,861,46%), :
:
:
. :
:

(p<0,05).
:
. / :
.
, ,

, :
, :
, .


1. .. . 1998. 352 .
2. Clark T.J.N., Hetzel M.R. Diurnal variation of asthma // Br J. Dis Chest.
1977. V. 71. P. 8792.
3. Lenney W., Wells N.E.J., O'Neill B.A. Burden of pediatric asthma //
Eur. Respir. Rev. 1994. 4. P. 4962.
4. Cochrane G.M., Clark T.J.N. A survey of asthma mortality in patients
between 35 and 65 in the greater London hospitals in 1971 // Thorax.
1975. V. 30. P. 300315.

5. Hetzel M.R., Clark T.J.H., Branthwaite M.A. Asthma: analysis of sud:


den deaths and ventilatory arrests in hospital // BMJ. 1977.
1. P. 808811.
6. Fitzpatrick M.F., Englemen H., Boellert F. et al. Effect of therapeutic
theophylline levels on sleep quality and daytime cognitive perform:
ance of normal subjects // Am. Rev. Respir. Dis. 1992. V. 145.
P. 13551358.
7. Gislason T., Almqvist M. Somatic diseases and sleep complaints // Acta

, . (%)

14 (70)

,
. (%)

6 (30)

,
, . (%)

13 (65)

, :, . (%)

6 (30)

bance in nocturnal asthma // Arch. Dis. Child. 1998. V. 78.


P. 413419.
19. .. .
1997. 31 .
20. Marcus C., Omlin K., Basinki D. et al. Normal polysomnographic
values for children and adolescents // Am. Rev. Respir. Dis. 1992.
V. 146. P. 12351239.
21. Uliel S., Tauman R. et al. Normal polysomnographic respiratory values
in children and adolescents // Chest. 2004. V. 125. P. 872878.
22. Chipps B., Mak H., Schuberth K. et al. Nocturnal oxygen satura:
tion in normal and asthmatic children // Pediatrics. 1980. V. 65.
P. 11571160.
23. Witmans M., Keens T. et al. Obstructive Hypopneas in Children
and Adolescents // Amer. J. Respirat. Critic. Care Med. 2003. V.
168. 1540 p.
24. Catteral J.R., Douglas N.J., Calverley P.M.A. et al. Irregular breath:
ing and hypoxaemia during sleep in chronic stable asthma // Lancet.
1982. 1. . 301304.
25. Zwillich C.W., Neagley S.R., Cicutto L. et al. Nocturnal asthma
therapy: inhaled bilolterol versus sustained:release theophylline //
Am Rev Respir Dis. 1989. V. 139. P. 470474.
26. Okudaira N., Kripke D.F., Mallaney D.J. Theophylline delays human
sleep phase // Life Sci. 1984. V. 34. P. 933938.
27. Rhind G.B., Connaughton J.J., McFie J. et al. Sustained release
choline theophylline in nocturnal asthma // BMJ. 1985. V. 291.
P. 16051607.
28. ..
// . . . . 2000.
29. Wiegand L. Mende C. et al. Salmeterol vs Theophylline. Sleep and
efficacy outcomes in patients with nocturnal asthma // Chest. 1999.
V. 115. 6. P. 15251532.

21
/ 1/ 2006

Med Scand. 1987. V. 222. P. 475481.


8. Janson C., Gislason T., Boman G. et al. Sleep disturbances in patients
with asthma // Respir Med. 1990. V. 84. P. 3742.
9. Klink M., Quan S.F. Prevalence of reported sleep disturbances in a
general adult population and their relationship to obstructive airways
disease // Chest. 1987. V. 91. P. 540546.
10. Janson C., De Backer W., Gislason T. et al. Increased prevalence of
sleep disturbances and daytime sleepiness in subjects with bronchial
asthma: a population study of young adults in three European countries
// Eur Respir J. 1996. 9. P. 21322138.
11. Fitzpatrick M.F., Martin K., Fossey E. et al.. Snoring, asthma and
sleep disturbances in Britain: a community:based survey // Eur
Respir J. 1993. 6. P. 531535.
12. Fitzpatrick M.F., Englemen H., Whyte K.F. et al. Morbidity in nocturnal
asthma: sleep quality and daytime cognitive performance // Thorax.
1991. V. 46. P. 569573.
13. Kales A., Beal G.N., Bajor G.F. et al. Sleep studies in asthmatic adults:
relationship of attacks to sleep stage and time of night // J Allergy.
1968. V. 41. P. 164173.
14. Montplaisir J., Walsh J., Malo J.L. Nocturnal asthma: features of
attacks, sleep and breathing patterns // Am Rev Respir Dis. 1982.
V. 125. P. 1822.
15. Kales A., Kales J.D., Sly R.M. et al. Sleep patterns of asthmatic
children: all:night electro:encephalographic studies // J Allergy.
1970. V. 46. P. 300308.
16. Avital A., Steljes D.G., Pasterkamp H. et al. Sleep quality in chil:
dren with asthma treated with theophylline or cromolyn sodium // J.
Pediatr. 1991. V. 119. . 97984.
17. Action asthma, young asthmatic survey. Uxbridge: Allen and
Hanbury's, 1993.
18. Stores G., Ellis A., Wiggs L. et al. Sleep and psychological distur:

..
:

22

:
. : :
3 6 / :
. 104 , :
( ), 249 ( ).
, :
, :
. : :
, . , :
: (81%), :
(4%). , :
3 / , 6 /
.
: ; ; 
; .
:
,
,

:
: :
;
: 194100, :,
. , 2,
. 8 (901) 320:26:97

()
() [1:4]. :
() :
32% [4]. :
. , :
,
() [5, 6].
40% [4, 7].
:
[1, 2].
() ,
3 6 / [6, 8]. ,
:
[9, 10]. , ,
: :
()
[11, 12].
(3 6 /) .

A.S. Kolbin
RF Health Ministry St.Petersburg State pediatric medical
academy

Pharmacoeconomical evalua
tion of invasive candidiasis
prevention in neonates with
very low body mass

INVASIVE CANDIDIASIS IN PREMATURE NEONATES IS CHARACTERIZED BY FRE:


QUENT AND ATTRIBUTIVE MORTALITY. THE AUTHORS CARRIED OUT CLINICAL
AND ECONOMIC ANALYSIS OF INVASIVE CANDIDIASIS PREVENTION IN
NEONATES WITH VERY LOW BODY MASS AT THE DELIVERY BY MEANS OF
FLUKONAZOL IN THE DOSES OF 3 AND 6 MG/KG. 104 NEONATES RECEIVING
PROPHYLACTIC TREATMENT WITH FLUKONAZOL COMPRISED THE MAIN GROUP,
249 PROPHYLAXIS FREE NEONATES COMPRISED THE CONTROL GROUP. THE
STUDY WAS PROSPECTIVE, ANALYTICAL, RANDOMIZED, COTROLLED AND CLINI:
CAL. SUCH PHARMACOECONOMICAL ANALYSES AS DISEASE COST, MINIMIZA:
TION AND EFFECTIVENESS OF EXPENSES WERE USED. THE STUDY DEMON:
STRATED THAT THE GREATEST DIRECT EXPENSES IN THE PROCESS OF CAN:
DIDIASIS TREATMENT WERE FOR HOSPITAL STAY (81%) AND THE LEAST ONES
FOR FLUKONAZOL (4%). PHARMACOECONOMICAL ANALYSIS OF THE OBTAINED
DATA SHOWED THAT PROPHYLACTIC DOSE OF 3 MG/KG OF FLUKONAZOL IS
MORE EFFECTIVE THAN THAT OF 6 MG/KG OR KEEPING PREMATURE PROPHY:
LAXIS FREE NEONATES IN THE ICU.
KEY WORDS: INVASIVE CANDIDIASIS, VERY LOW BODY MASS AT THE
DELIVERY, PHARMACOECONOMICAL ANALYSIS, PREMATURE NEONATES.

1.



[11, 12].

(Cost of illness /CoI). CoI:
(DC),

, 
(n = 353)

(n = 50)


(n=54)


(n = 249)

50

54

249

50

54

249

2.

(),

600:1500
(1330)

740:1500
(1250)

890:1500
(1200)

0,8

(),

24:32 (29)

26:32 (29)

27:32 (28)

0,99


(),

1:2 (1)

1:2 (1)

1:2 (1)

0,99

,
n (%)

136 (54)

22 (44)

26 (48)

0,108

23

:
( ). :
DC: :; : :
, ;
;
.
DC (:
, , :
), , :
, :
(, , , ,
) . DC :
, ,
.

. , :
,
. :
, , ,
.

:
(www.pharmindex.ru).

3. :


(),


(),

()

(),


(), /

15 (3)

1668 (35)

859 (15)

1471 (30)

21212 (53)

15 (3)

1468 (34)

952 (14)

1266 (31)

36365 (107)

/ 1/ 2006

::

. :
104 ,

() 1 : 2004
2005 . : :
,
1500
, 32 , 5 .
:
,
:
, :
1500 , ,
( :
50 /), :
. :
: :
3 / ( ), 6
/ ( ).
:
. 2
3 / 6 / 72
, 3:4 48 , 5:
24 . :
( ) 249 ,
1
1999 2002 . :
. (. 1)
CONSORT (Consolidated
Standards of Reporting Trails) [13].
. 2 , :

, .
:
, . , :
:
, .

. 3. :
,
3: , :
34: 35: .
( ), :
14 15 .

: 53 107
/ .

::
1, :
. :
.
. (1) (cost:mini:
mization analysis CMA). CMA: DC
DC . ,
:
( ) . (2)
(cost:effectiveness analysis,
CEA). CEA: DC/Ef ( :
/ , %). :
DC; Ef : (effi:
cacy , ).
, :
.

(Pfizer Int., LLC, ), :
( 50 , 2 /).

24



:

[1417]: (OR odds ratio)
, :
:

, :
( OR = 1,0, :
);
(ARR absolute risk reduction)
;
(RRR relative risk reduction) :

; , :
(NNT : number needed to treat ,
:
: ;
: 1/ARR); 95% :
; ( ); :
(); (
);
( :
).
Excel
MS Office. :
p0,05. :
,
www.hutchon.net.

::

(97,12%)

4.

*, .

Me

Me
1


, %

1200

25

30000

81


**

150

450

1,2

300

600

1,6

200

400

1,1

150

600

1,6

70

280

0,7

170

680

1,8

210

840

2,3

180

720

1,9

4570

12,3


2 / 50

60,48***

25

1512

25

175

0,5

800

2,2

37057/1337,79

100


( )
, /$

200

* : 1
** ,
*** 10 /, 1 504 ., 1$ =
27,7 . (www.pharmindex.ru).


.

. Me 10 // (
7 15), 25 (:
10 26). CoI . 4.
,
DC : 81%. :
DC :
12,3 4% :
. , CoI :
37057 (1337,79$). ,
10,8%,
CoI 14501,64$ [18].
. 
.
:
:
,
. . 5.
, CMA
DC: :,
, ,
DC.
1364$ : 1313$ = 51$. ,
, Me
18,34$ : 9,82$ = 8,52$.
.
CEA DC

. :

[1, 9, 19, 20]. :
.
. 6.
,
, , :
16,11 13,39 14,21. :
, :
:
(0,65 0,095 0,20 ).

:
, :
.
:

. 3 :

C. albicans C. parapsilosis 51%
34% [1, 4]. :

( 0,250,5 /
1 /) (
612 /) [3, 1921].

, :
, ., :

.
32:40% [19, 20].


.
:
:
90: XX [6, 810, 22, 23]. :
.

5.

*, .

1200

Me

Me

30

31

36000

99

37200

98,4


2
/ 50

18,14**/
36,29***

15

14

272,16

0,72

508,03

1,3

15

14

105

0,28

98

0,3

36377,16/
1313,25

100

37806,03/
1364,83

100

,
/$

* : 1.
** 3 /, 1 504 ., 1$ =
27,7 . (www.pharmindex.ru).
*** 6 /, 1 504 ., 1$ =
27,7 . (www.pharmindex.ru).

25
/ 1/ 2006

(89,16%) (p < 0,05; OR 0,25; NNT 12,5; RRR 73%;


ARR 8%). :
(3 6 /) 98 96% :
( > 0,05). :
:
(p < 0,05)
.

6.


(DC), $

1338

1313

1364

(Me), %

67:97 (83)

98

96

(CEA)*

16,11 (19,96:13,79)

13,39

14,21


(DC), $

54,58

9,34

19,3

(Me), %

67:97 (83)

98

96

(CEA)*

0,65 (0,56:0,81)

0,095

0,20

* .

26

: 2
72 ; 34: . 48 ; 5:
24 [9,10]. :
. :,
:
3 6 /. :,

. :
3
6 / .
:
.
,
.
1415
30 .
:
:

[11,12]. , 1980:2005 . :
24 :
[24, 25]. 11
:
( ) [5, 22 35]. :


.
. 7 11 :
, :

1. .., .., .. :
// . :
. . . 2005. .7, 2. . 189196.
2. .., ..
. . .: :
, 2004. 63 .
3. Groll A., Walsh T. Fungal infections in the pediatric patient // In:
Anaissie EJ, McGinnis MR, Pfaller MA, editors. Clinical mycology. 1
st ed. New York: Churchill Livingstone, 2003. P. 417442.
4. Kaufman D., Fairchild K. Clinical microbiology of bacterial and fun:
gal sepsis in very:low:birth:weight infants // Clinical Microbiolology
Reviews. 2004. V. 17, 3. P. 638680.
5. Buxton M., Dubois D., Turner R. et al. Cost implications of alterna:
tive treatments for AIDS patients with cryptococcal meningitis. Com:
parison of fluconazole and amphotericin B:based therapies // J.
Infect. 1991. V. 23, 1. P. 1731.

, . :
.
1
.
:
::
.
CMA [5, 35].
[31].
:
CMA,
CEA. ,
, :
3 / , :
6 /
:
.

:

( 1500 ).
3 /
:
.
: 2
72 , 3:4: 48 ; 5:
24 .

6. Kicklighter S., Springer S., Cox T. et al. Fluconazole for prophylaxis


against candidal rectal colonization in the very low birth weight infant
// Pediatrics 2001. V. 107, 2. P. 293298.
7. Lee B., Cheung P., Robinson J. et al. Comparative study of mortali:
ty and morbidity in premature infants (<1250 g) with candidemia or
candidal meningitis // CID. 1998. V. 27. P. 559565.
8. Kaufman D., Boyle R., Hazen K. et al. Fluconazole prophylaxis aga:
inst fungal colonization and infection in preterm infants // N Engl J
Med. 2001. V. 345, 23. P. 16601666.
9. .., .., .. . :
:
// . . . :
. 2003. . 4, 5. . 354359.
10. McGuire W., Clerihew L., Austin N. Prophylactic intravenous anti:
fungal agents to prevent mortality and morbidity in very low birth
weight infants (Cochrane Review). In: The Cochrane Library, Issue 1

atments for systemic fungal infections: a systematic review of the litera:


ture // Pharmacoeconomics. 2004. V. 22, 7. P. 421433.
25. van Gool R. The cost of treating systemic fungal infections //
Drugs. 2001. V. 11. P. 4956.
26. Krupova Y., Novotny J., Sabo A. et al. Aetiology, cost of antimicro:
bial therapy and outcome in neutropenic patients who developed
bacteraemia during antimicrobial prophylaxis: a case:control study
// Int J Antimicrob Agents. 1998. V. 10, 4. P. 313316.
27. Manfredi R., Mastroianni A., Coronado O. et al. Fluconazole as
prophylaxis against fungal infection in patients with advanced HIV
infection // rch Intern Med. 1997. V. 157, 1. P. 6469.
28. Poirier J., Hardy S., Isnard F. et al. lasma itraconazole concentra:
tions in patients with neutropenia: advantages of a divided daily dos:
age regimen // Ther Drug Monit. 1997. V. 19, 5. P. 525529.
29. Sajben P, Minarik T, Tomasik E, et al. Fluconazol plus ofloxacin in
prophylaxis of infections in patients with acute leukemia: a comparati:
ve study // Support Care Cancer. 1993. V. 1, 4. P. 214216.
30. Schaffner A., Schaffner M. Effect of prophylactic fluconazole on the
frequency of fungal infections, amphotericin B use, and health care
costs in patients undergoing intensive chemotherapy for hematologic
neoplasias // J. Infect Dis. 1995. V. 172, 4. P. 10351041.
31. Scharfstein J., Paltiel A., Freedberg K. The cost:effectiveness of flu:
conazole prophylaxis against primary systemic fungal infections in AIDS
patients // Med Decis Making. 1997. V. 17, 4. P. 373381.
32. Schroder C., de Vries E., Mulder N. et al. Prevention of febrile leucope:
nia after chemotherapy in high:risk breast cancer patients: no significant
difference between granulocyte:colony stimulating growth factor or cipro:
floxacin plus amphotericin B // JAC. 1999. V. 43, 5. P. 741743.
33. Skinner J., Harris C., Aaron M. et al. Cost:benefit analysis of
extended antifungal prophylaxis in ventricular assist devices //
ASAIO J. 2000. V. 46, 5. P. 587589.
34. Tollemar J., Hockerstedt K., Ericzon B. et al. Prophylaxis with liposo:
mal amphotericin B (AmBisome) prevents fungal infections in liver
transplant recipients: long:term results of a randomized, placebo:con:
trolled trial // Transplant Proc. 1995. V. 27, 1. P. 11951198.
35. Wakerly L., Craig A., Malek M. et al. Fluconazole versus oral polyen:
es in the prophylaxis of immunocompromised patients: a cost:minimi:
zation analysis // J. Hosp Infect. 1996. V. 33, 1. P. 3548.

27
/ 1/ 2006

2003. Oxford: Update Software.


11. .. , .., .., .. :
: . .: : , 2004. 404 .
12. :
// . .. .
., 2000, . 223260.
13. Bennett J. The Consolidated Standards of Reporting Trials (CON:
SORT): Guidelines for reporting randomized trials // Nurs Res. :
2005. v. 54, 2. P. 128132.
14. .. :
.: .: , 1978. 296 .
15. ., ., . :
. . . .. : .:
, 1998. 347 .
16. Altman D. Confidence intervals for the number needed to treat //
BMJ. 1998. V. 317. P. 13091312.
17. Bland M., Altman D. Statistics Notes: The odds ratio // BMJ.
2000. V. 320. 1468 p.
18. .., .., .., .. :

32 // . . .
. 2005. . 7, 1. . 97102.
19. .., .., ..
:
//
. 2005. 1. . 4248.
20. Frattarelli D., Reed M., Giacoia G. et al. Antifungals in systemic
neonatal candidiasis // Drugs. 2004. v. 64, 9. P. 949968.
21. Red Book: 2003 Report of the Committee on Infectious Disees:
es. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics;
2003. P. 927.
22. Sims M., Yoo Y., You H. et al. Prophylactic oral nystatin and fungal
infections in very:low:birthweight infants // Am J Perinatol. 1988.
V. 5. P. 3336.
23. Wainer S., Cooper P., Funk E. et al. Prophylactic miconazole oral
get for the prevention of neonatal fungal rectal colonization and syste:
mic infection // Pediatr Infect Dis J. 1992. V. 11. P. 713716.
24. Dixon S., McKeen E., Tabberer M. et al. Economic evaluations of tre:

.. , .. , .. , .. , .. , .. ,
.. , ..


:
2004 2005 .
. , ,
:
. :
( ),
, , :
. ,
, :
.

28

: , :

, , , ,
.
10: J30.1 , :
; J30.2
; J30.3 ; J30.4
.
: ;
:
; .

:
. ,

18:38% [15]. :
2040 , :

40%. . 5

,
[68].

,
(
). :
:
.

.



()

:
, .
:
:
. :
46: . :
.
( 4 )
(. ).

:






, , :
(:
, , , )

:
:
.

,
[9].

, :
.

(, , , :
)
, :
:
.
:
( ),
.

2 9
[10]. :

( , , ).


,
: IgE.

:
, , ,
, , /:
, , :
, .




;
: .


IgE: in vivo;
.
(:
/ :
().
,
.

/ .
: ,
, IgE:
[11]. , :
:
20 [12].
710
. :
:
.
, :
:
.

: (
) :
IgE: . 25%

. ,
. :

A [68].


, :
D ( ).
,

,
( ,
,
). :
.


IgE D.

.

.

:
, , . :
23: 5: :
. , 2 ,
.
() :
.
:
[13].
, :
, . :

[14]. ,
, , , . :
,
.
, ,
, ,
, , . :
:

.
:
,
. :
,
: .
,
,
.
:
, :
,
. :
, :
, :
, :
,
[15].

, , :
, ,
, :
, ,
. :
:
.
:
, :
, ,
/ , :
/ , , ,
.


:
[68].

29
/ 1/ 2006


( ,
, , ).

, :, .
.

,
(

).

( ,
, ,
, ) [68].

(
),
.


.

30



: , :
:
.
,
.
( , :
). :
(, , :
) . ,
:,
, .
:

,
,
.

.
.

, :
, ,
, ,
50%.
, (,
).
, ,
, , (
), .
. :
:

, ,
[16].

( 60 ), 1 [17].
:
, , :
,
,
A[18].

50%.

.
HEPA:
[19].
:
(,
, ,
3% ).
[20].
:
.

.
.
.

[21].
:
,
.
HEPA:
, , :
[22].
:
() .
, :
20 [23].




,
(. ).

+++

++

+++

+/:

+++

+++

+++

++

+/:

+++


()
;
,
, , , .
23:
, 23:
.
. :
.
:
1 .
5:10% ,
,
, :
.
. :
:
.
, :

::
[24].

. :
, :
.
:


:
, , ,
,
.
,
, :
.
(:
, , )
: (:
, )
( , , :
) .
(:
, )
.
1 6 2,5 2
5 ,
6 10 5 2 .
2 .
30 5 1 ,
30 10 1 .


.
:
:
6 11
[29]. 6 30
12 , 12 120 1 .


,
, :
, ,
[30:32]. :
2 12 2,5 1 :
, 12 5 1 .
:
:
, , :
, . :

( ).
:

.
()

.
, .
5
1 2 .

, :
, , ,
[24, 33].

1 2
4 .
3 ,
3 .
, :
.
23 .
:
( ). :
( , , :
) .



,

:
.
.

(:
, , ) :
,
37 ,
:
.
.


1 .


. ,

, :
[68].

31
/ 1/ 2006


:
[17, 18]. :
:
( )
.
:
:
, .
, , :

[25:27].
2: ,
1 (50 )
1 . :
,

[28].
4 , :
1 (50 ) 1
, 200 .
6 ,
12 (50100 ) 24 :
.
6 , :
1 (50 ) 1
, 200 .
:
. (:
) :
,
,
.

, .



,
.
( :
, ) (
) [3437],

. :
:
.
5 . :
3 5 . :
, :.
, ,
3060
( :
). ,
,
:
.

32


[9]:
,
;
,
;
;
(, :
), .

:
.

.

1. .. // Consilium medicum.
2000. 2(8). . 338344.
2. ..
// . 2001. 3.
. 2227.
3. ..

// . 2002. 1(2).
. 100101.
4. .. :

// . . ... . . . 2000. 36 .
5. .., .., ..
.
,
// .
1998. 4. . 410.
6. Baker J.R. (ed.). Primer on Allergic and Immunologic Diseases (4th
Ed.). JAMA, 1997. 278 (22). P. 17992034.
7. Stroebel R., Graft D., Takahashi M. et al. Health Care Guideline:
Rhinitis. Bloomington, MN: Institute for Clinical Systems
Improvement (ICSI), 2000. [www.icsi.org/guidelst.htm#guidelines]
Evidence based guideline and algorithms for treatment of allergic
and non:allergic rhinitis.
8. Dykewicz M.S., Fineman S., Nicklas R. et al. Diagnosis and
Management of Rhinitis: Parameter Documents of the Joint Task Force
on Practice Parameters in Allergy, Asthma, & Immunology. Annals of
Allergy, Asthma, and Immunology, 1998; 81 (Part II). P. 463:468.
9. : . ., 2002.
. 6870.
10. Dykewicz M.S., Fineman S., Skoner D.P. et al. Diagnosis and man


( :
, :
).
, :
.

(, :
) .
/ :
.
.
/
:
:
.
, :
, , /:
.
,
[68].

:
: ,
1 57 ; 1 6
;
: 1 36 [9].


, ,
,
:
[38].

agement of rhinitis: Complete guidelines of the Joint Task Force on


Practice Paramaters in Allergy, Asthma and Immunology. // Ann.
Allergy Asthma Immunol. 1998. V. 81 P. 478.
11. Bernstein I.L., Storms W.W. Practice parameters for allergy diag:
nostic testing. Joint Task Force on Practice Parameters for the
Diagnosis and Treatment of Asthma. The American Academy of
Allergy, Asthma and Immunology and the American College of Allergy,
Asthma and Immunology. // Ann. Allergy Asthma. Immunol. 1995.
V. 75. P. 543.
12. Linna O., Kokkonen J., Lukin M. A 10:year prognosis for childhood
allergic rhinitis. // Acta Paediatr. 1992. V. 81. P. 100.
13. Togias A., Proud D., Kagey:Sobotka A. et al. Cold dry air (CDA) and
histamine (HIST) induce more potent responses in perennial rhinitics
compared to normal individuals. // J. Allergy. Clin. Immunol. 1991.
V. 87. P. 148.
14. Settipane R.A., Lieberman P. Update on nonallergic rhinitis. //
Ann Allergy Asthma Immunol 2001. V. 86. P. 494.
15. Jacobs R.L., Freedman P.M., Boswell R.N. Nonallergic rhinitis with
eosinophilia (NARES syndrome). Clinical and immunologic presenta:
tion. // J. Allergy Clin. Immunol. 1981. V. 67. P. 253.
16. Warner J.A. Controlling indoor allergens. Pediatr. Allergy Immunol.
2000. V. 11. P. 20819.
17. McDonald L.G., Tovey E. The role of water temperature and laundry
procedures in reducing house dust mite populations and allergen content
of bedding. // J. Allergy Clin. Immunol. 1992. V. 90. P. 599608.
18. Terreehorst I., Hak E., Oosting A.J., Tempels:Pavlica Z. Evaluation
of impermeable covers for bedding in patients with allergic rhinitis.
// N. Engl. J. Med. 2003. P. 349237.
19. Kalra S., Owen S.J., Hepworth J., Woodcock A. Airborne house
dust mite antigen after vacuum cleaning [letter]. // Lancet 1990.
P. 336449.

Cochrane library. 2003. V. 26, Issue 5. P. 196201.


29. Wahn U., Meltzer E.O., Finn A.F. Jr. et al. Fexofenadine is effica:
cious and safe in children (aged 611 years) with seasonal allergic
rhinitis.[erratum appears of Allergy & Clinical Immunology. 2003.
V. 111. 4. P. 7639.
30. Corren J., Salmun L.M. Quality of life in patients with seasonal
allergic rhinitis is improved by desloratadine (abstract). // Allergy.
2000. 55 (suppl 63). 191. Abstract 676.
31. Heithoff K., Meltzer E.O., Mellars L., Salmun L.M. Desloratadine
improves quality of life in patients with seasonal allergic rhinitis. (abstract).
J. Allergy Clin. Immunol. 2000 105: S383384. Abstract 1121.
32. Salmun L.M., Lorber R., Danzing M., Staudinger H. Efficacy and
safety of desloratadine in seasonal allergic rhinitis (abstract). //
Allergy Clin. Immunol. 2000. 105: S384. Abstract 1123.
33. Van Bavel J., Findlay S.R., Hampel F.C. Jr. et al. Intranasal fluticas:
one propionate is more effective than terfenadine tablets for season:
al allergic rhinitis. // Arch. Intern. Med. 1994. V. 154. P. 2699.
34. Weber R.W. Immunotherapy with allergens. JAMA 1997. V.
278. P. 1881.
35. Li J.T. Immunotherapy for allergic rhinitis. // Immunol. Allergy
Clin. N. Am. P. 2000. V. 20. P. 383.
36. Leynadier F., Banoun L., Dollois B. et al. Immunotherapy with a
calcium phosphate:adsorbed five:grass:pollen extract in seasonal
rhinoconjunctivitis: a double:blind, placebo:controlled study. // Clin.
Exp. Allergy. 2001. V. 31. P. 988.
37. Walker S.M., Pajno G.B., Lima M.T. et al. Grass pollen
immunotherapy for seasonal rhinitis and asthma: A randomized,
controlled trial. // J. Allergy Clin. Immunol. 2001. V. 107. P. 87.
38. ..
: . 2004.

33
/ 1/ 2006

20. Woodfolk J.A., Hayden M.L., Miller J.D. et al. Chemical treatment of
carpets to reduce allergen: a detailed study of the effects of tannic acid on
indoor allergens. // J. Allergy Clin. Immunol. 1994. V. 94. P. 1926.
21. Custovic A., Green R., Fletcher A. et al. Aerodynamic properties of
the major dog allergen Can f 1: distribution in homes, concentration,
and particle size of allergen in the air. // Am. J. Respir. Crit. Care Med.
1997. V. 155. P. 948.
22. Green R., Simpson A., Custovic A. et al. The effect of air filtration
on airborne dog allergen. // Allergy 1999. V. 54. P. 4848.
23. Wood R.A., Chapman M.D., Adkinson N.F. Jr, Eggleston P.A. The
effect of cat removal on allergen content in household:dust samples.
J. Allergy Clin. Immunol. // 1989. V. 83. P. 7304.
24. Grossman J., Banov C., Bronsky E.A. et al. Fluticasone propionate
aqueous nasal spray is safe and effective for children with seasonal
allergic rhinitis. // Cochrane Library. 1993. V. 92. P. 5949.
25. Mandl M., Nolop K., Lutsky B.N. Comparison of once daily mometa:
sone furoate (Nasonex) and fluticasone propionate aqueous nasal
sprays for the treatment of perennial rhinitis. Annals of Allergy, Asthma
and Immunology, Cochrane library. 1997. V. 79; 3; P. 237245.
26. Hebert J.R., Nolop K., Lutsky B.N. Once:daily mometasone
furoate aqueous nasal spray (Nasonex(TM)) in seasonal allergic rhini:
tis: An active: and placebo:controlled study. Allergy // European
Journal of Allergy and Clinical Immunology, Cochrane library. 1996.
V. 51 8. P. 569576.
27. Fokkens W.J., Cserhati E., dos Santos J.M., Praca F., van Zanten
M., Schade A., Simon G. Budesonide aqueous nasal spray is an effec:
tive treatment in children with perennial allergic rhinitis, with an
onset of action within 12 hours. Annals of Allergy, Asthma, &
Immunology, Cochrane library. 2002. V. 89. 3. P. 27984.
28. Stuck B., Hummel T., Hecksteden K., et al. Mometasone furoate
in the treatment of seasonal allergic rhinitis // Allergologie,

.. , .. , .. , .. , .. , .. ,
.. , .. , .. , ..

34

( , :
/) :
, ,

,
:
. :
:
, , :
, , ,
[1].
:

,
, ,
,
[1].
10: L20 .
: ;
; :
().


3 ,
, 10:15% 5 15:
20% .
. , :
, :
[24].
,
81% , , 59%
,
, 56% :
[5].

(
, :
)


, ,
:
, [6].

:

[6].

, ,
[6].
, :
,
/ :
:
[7],
3 :

4,5 D[8].

,

Lactobacillus sp. :
A[7,9,10].
:

,
,

C[11].
, :
( :
, :
, )
, , 2
:

:
A[7, 12, 13].


. :
(EAACI)
(2001) :
, :
, :
/, :
.
/

IgE, [14].

:
; :
, ,
.
,
, :

.

:
1980 . (Hanifin, Rajka);

3 4 :
3 23 .
:
2003 .
:
[2].
( ):
;
(, , ):
:

, (,

; ,
: );
.
(
, ):
;
:

;
IgE:;
.
( :
,

):
(
, );
,
, ;
, ;
( ,
);
, [2].

SCORAD
.

(
1% ).
. :
6 (,
/, /, , :
, ). 0 3
(0 , 1 , 2
, 3 ; :
). ,
.
0 ( ) 18
( 6 ).

.
.
7 . :
:
10: , ,
, ,
3 . :
0 20.
: /5 + 7/2 + .
SCORAD
0 ( :
) 103 ( :
).

IgE
( ).
(:,
, ) IgE::

/ 1/ 2006

35

[15].
2
.

, :
,
. :
.
2:6 :
;
, / :
. .
: 50% ,
, 2
.
.
:
.
: ,
:
. :
:
.
, :
. :

46
[16].

SCORAD (Sco:
ring Atopic Dermatitis), EASY (Eczema Area and Severity Index),
SASSAD (Six Area Six Sign Atopic Dermatitis Severity Score).

SCORAD (),
(), :
(B) (C).
.
(%),
(. ., :
2 ). :

36

,
.


:
,
72 5 :
[17].

:
, :
[16].
IgE:
(, .) :
, ;
:
;

:
;


.
: ,
:
: [16].


, , :
, , , :
( , :
) [18].

: ,
, :
, : :
, , :

, .
: ,

, ,
.
:
:
, , :
: :
, . ,
(20% 10%
, , ), :
, :
) [18].
: :
.
: :
: .
: .
: ,
.
: :
, ,
.


:
:
. :
, , :
.

[1].

[1]. :
;

;
[1].

( )

IV ( )

( ) 0,05% ,
(I )

III ()

( ) 0,005% (III )
( ) 0,05% ,
(I:III )

II ( )

( ) 0,05% , (V )
( ) 0,05% (IV )
( ) 0,1% , (V )
( ) 0,1% , , (IV )
( ) 0,1% (IV )
0,1% , , ,

I ()

( ) 1%, 2,5% , (VII )



,
:
;
;
();
,
, , :
;
( );
;
( ) [2].
. 10% :

:
D[19],

:
D[19].
:
.
[6].
:
, :
IgE: , :

A[7]. :
, , :
, ,
,

A[7]. , ,
, :

,
A[7].
(:)
, :
.
A/B
, BA[7].
A1 ( 340400
), , :
,
1 :
, A/B:A[7].
PUVA: ( ::
) :
12 C[7].
: :
:
[11].
: :

, ,
D[7].



:
, :

A[7].
, ,
, ,
.
,
, :
,
.
:
.
, 2 , :
, , :
[1].
:
,
.
6,
D[2]. 3:4
:
D[16].
() :
A[8]. :

, , :
:
A[7].

2 :
C, ,
:

D[11].
(~3 ) :
, :
(~7 ) A[6, 21].
, :
, :
,
:
C[11].

(:
2 ) :
,
,
A[7, 20]. :
:
A[8].

(, , )
:
A.
D[7]. ::


2 [2123].
, :
, :
, :
, :
( I:IV

37
/ 1/ 2006


, :
.
, :
.
.

.
.

38

, : I:VII), 4 (. .):
( I , IV );
( II III , III );
( IV V , II );
( VI VII , I ).

.
:
.
:

III , :
II .

I II
, : I .
IV 14 [17,24].
(
) ( :
)
(1% )*. :
, : :
. :
:
( 2, 4, 10, ) :
:
. :
, :
, . :

.
A[7]. :
, ,
:

A[7];
,
, :
[1, 2527].
;
A[7]. 3
, , :
, .
, :
, :
, , :
, , :
[1]. , :
, :

, :

[1, 2].
:
C[7] :
:
.
. :
,

, .
:
A[7].

D,
,
, [7, 11].


, 

:
( )
A [7, 11].

:
, , :
A[6]. :
, :
,
A[7]. ,
:
[11].

:
[11].

:
S.
aureusA[7]. :
:
S. aureus [7].


[7].
:
:
A[6].
(, :
) [2].


, :
.
:
, , :
:
A[7].
:
( 1
)C[28]. 2,5 //,
2 .

5 //.
:

, :
D[7, 25].
:
() ()
:
. ,
:
, :
,
.
. :
, :
, , :
[2, 7].
, :
,
,


:
;
,
;

.
:
[2, 17].
.
:
, .
.

.

. :
(510 ), ( ) .
.
.
,
.
:
,
.
:
.
, :
, :
.
:
, .

1. Ellis C., Luger T., Abeck D. et al. International Consensus Conference
on Atopic Dermatitis II (ICCAD II): clinical update and current treatment
strategies. Br. J. Dermatol. 2003 May; 148 Suppl. 63:310.
2. Leung D. Pathogenesis of atopic dermatitis // J. Allergy Clin. Immunol.
1999. V. 104 (Suppl.). P. 99108.
3. The Allergy Report. The American Academy of Allergy, Asthma & Immu:
nology 2000.
4. Kramer M.S., Kakuma R. Maternal dietary antigen avoidance during
pregnancy and/or lactation for preventing or treating atopic disease in the
child (Cochrane Review). The Cochrane Library, Issue 2, 2004.
5. Smethurs D., Macfarlane S. Atopic eczema. Clinical Evidence 2002.
P. 17851803.
6. Guidelines of Care for Atopic Dermatitis J. Am. Acad. Dermatol.
7. Kalliomaki M., Salminen S., Arvilommi H. et al. Probiotics in primary
prevention of atopic disease: a randomized placebo:controlled trial. Lan:
cet. 2001. 357(9262). P. 10761079.
8. Rautava S., Kalliomaki M., Isolauri E. Probiotics during pregnancy and
breast:feeding might confer immunomodulatory protection against ato:
pic disease in the infant. J. Allergy Clin. Immunol. 2002. 109(1).
P. 119121.
9. Ricci G., Patrizi A., Specchia F. et al. Effect of house dust mite avoidan:
ce measures in children with atopic dermatitis. Br. J. Dermatol. 2000.
143(2). P. 379:384.
10. Friedmann P.S., Tan B.B. Mite elimination:clinical effect on eczema.
Allergy. 1998. 53(48 Suppl). P. 97100.
11. Consensus Conference on Pediatric Atopic Dermatitis J. Am. Acad.


.
.
.
.
:
.
.
.
,

.
.

,
.

, .

:
, 50% 1:
[1].
: 60% :
,
[29].
, , :
1: , :
[30]. ,
,
,
[31]. :
:
,
[31, 32].

[33].
:
:
, [34].

Dermatol. 2003. 49. P. 108895.


12. Atopic dermatitis in children: clinical picture and diagnosis
EBM Guidelines 2000.
13. A revised nomenclature for allergy. An EAACI position statement from:
the EAACI nomenclature task force. Allergy. 2001. 56. P. 813824.
14. Shaw J.C. Atopic dermatitis. UpToDate December 29, 2003.
15. Lewis:Jones M.S., Finlay A.Y., Dykes P.J. The Infants' Dermatitis Quality of
Life Index // Br. Dermatol. 2001. V. 144. P. 104110.
16. Su J.C., Kemp A.S., Varigos G.A. et al. Atopic eczema: its impact
on the family and financial cost // Arch. Dis. Child. 1997.
V. 76. P. 159162.
17. Hanifin J.M. Epidemiology of Atopic Dermatitis // Immunol. Aller:
gy CM NA. 2002. V. 22. P. 124.
18. Graham:Brown R.A.C. Atopic dermatitis: Predictions, expectations
and outcomes // Am. Acad. Dermatol. 2001. V. 45. P. 561563.
19. Vickers C.F.H. The natural history of atopic eczema // Ada Derm
Venereal (Suppl.)(StocWi). 1980. V. 92. P. 135.
20. Bergmann R.L., Edenharter G., Bergmann K.E. et al. Atopic Der:
matitis in early infancy predicts allergic airway disease at 5 years //
Clin. Exp. Allergy. 1998. V. 28. P. 965970.
21. Leung D.Y., Soter N.A. Cellular and immunologic mechanisms in
atopic dermatitis // J. Am. Acad. Dermatol. 2001. V. 44
(Suppl. 1). P. S1S12.
22. Hoare C., Li Wan Po A., Williams H. Systematic review of treat:
ments for atopic dermatitis // Health. Technol. Assess. 2000. :
V. 4. : P. 1191.

39
/ 1/ 2006

[11].

:
,
, .


, :
[7, 11].

23. Atopic eczema in primary care. MeReC Bulletin V. 14


number 1, 2003.
24. Harper J.I., Ahmed I., Barclay G. et al. Cyclosporin for severe
childhood atopic dermatitis: short course versus continuous therapy.
Br. J. Dermatol. 2000; 142(1). P. 5258.
25. Kapp A., Papp K., Bingham A. et al. Long:term management of atopic
dermatitis in infants with topical pimecrolimus, a non:steroid anti:inflam:
matory drug // Allergy Clin. Immunol. 2002. V. 110. P. 277284.
26. Meurer M., Folster Hoist R., Wozel G. et al. Efficacy and safe:
ty of pimecrolimus cream in the long:term management of atopic
dermatitis in adults: a six:month study // Dermatology. 2002.
V. 205. P. 271277.
27. Wahn U., Bos J.D., Goodfield M. et al. Efficacy and Safety of
Pimecrolimus Cream in the Long:Term Management of Atopic Der:
matitis in Children // Pediatrics. 2002. V. 110 (el.).
28. Atopic dermatitis in children: clinical picture and diagnosis EBM.
Guidelines, 2000.
29. Thomas K.S., Armstrong S., Avery A. et al. Randomized controlled
trial of short bursts of a potent topical corticosteroid versus prolon:

ged use of a mild preparation for children with mild or moderate ato:
pic eczema. BMJ. 2002. 324(7340). P. 768.
30. Hanifin J.T., Gupta A.K., Rajagopalan R. Intermittent dosing of flu:
ticasone propionate cream for reducing the risk of relapse in atopic
dermatitis patients. Br. J. Dermatol. 2002. 147(3). P. 528537.
31. Matsuda K., Katsunuma T., Iikura Y. et al. Adrenocortical function
in patients with severe atopic dermatitis. Ann. Allergy Asthma Immu:
nol. 2000. 85(1). P. 3539.
32. Friedlander S.F., Hebert A.A., Allen D.B. Safety of fluticasone pro:
pionate cream 0.05% for the treatment of severe and extensive ato:
pic dermatitis in children as young as 3 months. J. Am. Acad. Derma:
tol. 2002. 46(3). P. 387393.
33. Tan M.H., Lebwohl M., Esser A.C. et al. The penetration of 0.005%
fluticasone propionate ointment in eyelid skin. J. Am. Acad. Dermatol.
2001. 45(3). P. 392396.
34. Friedmann P.S. Allergy and the skin. II Contact and atopic ecze:
ma. Clinical review.
35. Ross St. C. Barnetson, Maureen Rogers. Childhood atopic ecze:
ma BMJ. 2002. 324. P. 13769.

40


10th World Congress of Child
Neurology
10

Epidemiology 2006 (International


Epidemiological Association (IEA
EEF)
2006

19th Congress of the European


College of
Neuropsychopharmacology
19

1116 2006 .
,
: Events International
Meeting Planners
: 514:286:0855
: 514:286:6066
E:Mail: info@eventsintl.com

28 01 2006 .
,
: Mrs. Evelyn Maurer, FBU
Conference Office, PO Box 80125
3508 TC Utrecht, The Netherlands
: 31:302:532:728
: 31:302:535:851
E:Mail: euroepi2006@fbu.uu.nl

1619 2006 .
,
: European College of
Neuropsychopharmacology
E:Mail: secretariat@ecnp.nl

.. 1, .. 2
: . .. ,
2 ,

:



. 1974 .
,
. , :
:
, :
. :
95% ,
.
: , .

14 1776 ., (Edward Jenner)
, :
, [1].
1974 . :
().
, :
:
,

[13].
95%
, , , , ,
, .
. ,
, Haemophilus influenzae
b , , , :
[4].
30: :
. 1 [4, 5]. :
99% . :
,
, 2003 .
381 (1964 .
1 250 552, 2003 . 3291), 225 (1932 . 147 900, 2003 .
665). 1997 .
, 1958 . 10 363 .
:
.
:
,
.

B.F. Semionov1 , V.K. Tatochenko2


RAMS I.I. Mechnikoff vaccines and sera research institute,
Moscow
2
Scientific Center of Childrens Health, Russian Academy of
Medical Sciences, Moscow

Immunoprophylaxis of pediatric
infections: results and
prospects.

VACCINATION IS THE EASIEST AND ECONOMICALLY EFFECTIVE MEANS OF


CONTROL OF INFECTIOUS DISEASES IN ALL SOCIAL POPULATION GROUPS
OF INDUSTRIAL AND DEVELOPING COUNTRIES. THE IMPLEMENTATION OF
THE WHO CONCEPTION OF COMPREHENSIVE IMMUNIZATION PROGRAM
ADOPTED IN 1974 HAS BROUGHT ABOUT A SIGNIFICANT DECREASE OF THE
MAIN PEDIATRIC INFECTIONS INCIDENCE. WHILE FORMERLY MASS IMMU:
NIZATION WAS AIMED AT THE DECREASE OF PEDIATRIC MORBIDITY AND
MORTALITY CAUSED BY INFECTIONS, NOWADAYS IMMUNOPROPHYLAXIS IS
MAINLY AIMED AT THE MAINTENANCE OF THE ACHIEVED BENEFICIAL EPI:
DEMIOLOGICAL SITUATION. IT NECESSITATES THE CONTINUATION OF MASS
VACCINATION OF NOT LESS THAN 95% OF CHILDREN DURING THEIR FIRST
YEARS OF LIFE AS WELL AS THE ESTABLISHMENT OF PARTNER RELATIONS
WITH PARENTS AND MASS MEDIA.
KEY WORDS: IMMUNOPROPHYLAXIS, PEDIATRIC INFECTIOUS DISEASES.

41
/ 1/ 2006

:
,
,
. .. ;
: 105064, ,
. . , . 5,
. (495) 917:49:00


[6]. :
:

.
. 2.
1.
1974:2003 .


19742003 ., %

100

100

99,99

99,99

75

99,98

98

99,87

99,97

94,5

99,5

99,99

42
2.
(95% )

19751980

35 700

19931996

104 250

1990

182

19901991

36

1991

111

1992

27

()

1995

144

2000

14

2000

135

2002

2501

2002

140

19931996 .
(104 250 ).

.
,
.
:

. , 90: XX
8 000 000 ,
. :
[6].
.. ,

,
,
10% [6]. ,
. .. :
, 57% :
. 2030% , 1530%
, 15% , :
[6].
90: XX * ** :
:
,
.

:
. , :
, :
. ,

. :
, :

. :

, , :
, , ,
,

( , ),
:
: [6].

, :


. , :
, :
:
[7]. :
, :
.
1. :
.
(1 750 000 ) [4], :
10:11 . ,
, :
.
2.
() [8]. :
:
. 14 .
(2000,
2004 .) (2004 .). 12 :
( 19821993 .),
(1998 .), (1999 .), (20002001 .),
(2001 .), (20012002 .),
(2003 .), (2003 .), (2003 .),
(2003 .), (2003 .), (2003 .).

* .. ( ), ..
( . .. , ..
( ), ..
( ), ..
(
. .. ), .. (
) .
** (CDC, ),
,
, .

3.

[9]

[10]

[10]

[11]

[12]

1:2
, :
. :
, :
. :
8085%,
.
,
,

(. 3).

612 :
HbsAg 10,3 1,7% 4:
[9].
1
, :
,
,
[10].
.
.. .
:
0,89
0,69 :
[11],
.
C. Gruber et al.

[12].
, :
,


2 3 .

. :
, 2006 . 27
37
[13]. , (19) :
:
: 14
*, 5 :
**.


. ,

.
:
,
.
, ,
, :
,
:
.

,
.
:
, :
[14].
:
:
, ,
, [14, 15].
, :
, N. Andrews et
al. [16], 108 866 , :
19881997 . , :
. :
,
: , ,
, ..
:
.

. :
.


95% .
.
:
:
:
.
:
.

* , , , ,
, , , , ,
, , ,
, Haemophilus influenzae b, .
** , ,
, , ( ).


1. Vaccines / Eds. Plotkin S.A., Orenstein W.A. 3 ed. Philadelphia,
London, Toronto, W.B.Sanders Company, 1999. 1230 p.
2. .., .., .. . :
// . . 1996.
5. . 110114.
3. The eradication of infections diseases / Eds. Dowdle W.R., Hopkins

43
/ 1/ 2006

D.R. West Sussex, England; John Wiley Sons Ltd. 1998. 205 p.
4. Orenstein W.A., Wharton M., Bart K.J. et al. Immunization // Prin:
ciples and practice of infectious diseases / eds. Mandell G.L., Ben:
nett J.E., Dolin R. Elsevier Churchill Livingstone, 2005. V.2.
P. 35573588.
5. (19132002 .) /
. ., 2003. 69 .
6. / . ..
, .. ., 2001. 338 .
7. Global polio eradication initiative. Strategic plan 20012005.
WHO. Geneva, 2000. 21 p.
8. Kew O.M., Wright P.E., Agol V.I. et al. Circulating vaccine:derived
polioviruses: current state of knowlege // Bull. WHO 2004. V. 82.
: 1. : P. 1623.
9. Cang M.N., Chen C.J., Lat M.S. et al. Universal hepatitis B vaccina:
tion in Taiwan and incidence of hepatocellular carcinoma by children
// N. England. J. Med. 1997. V. 336. P. 18551859.
10. Jaeckel E., Manns M., von Herrath M. Viruses and diabetes //
Ann.Y. Academy Science. 2002. V. 958. P. 725.
11. .., .., .. . :

44

// .
2001. 5:6. . 3944.
12. Gruber C., Jlli S., Lan S. et .al. Transient suppression of atopy in
early childhood is associated with high vaccination coverage //
Pediatrics 2003. V. 111, 3. P. 283288.
13. Plotkin S.A. Vaccination in the 21 century // J. Infec. Dis. 1993.
V.168. P. 2937.
14. Taylor B., Miller E., Farrington C.P. et al. Autism and measles,
mumps and rubella vaccine; no epidemiological evidence for causal
association // Lancet 1999. V. 353. P. 20262029.
15. Parker S., Schwartz B., Todd J. et al. Thimerosalcontaining vac:
cines and autistic spectrum disorder: a critical review of published
original data // Pediatrics 2004. V. 114, 3. P. 793804.
16. Andrews N., Miller E., Grant A. et al. Thimerosal exposure in
infants and development disorders: a retrospective cohort study in
the United Kingdom does not support a causal association // Pediat:
rics 2004. V. 114, 3. P. 584591.
17. WHO Global advisory committee on vaccine safety: response to
the paper by M.A. Hernan and others in Neurology 14 September
2004 issue entitled Recombinant hepatitis B vaccine and risk of
multiple sclerosis (2004)

29 2005 . N 7052

28 2005 .
N 601

28.09.2005 . N 601

, ()
,

I.

II.

+ +
+ +

;
;

,
;

47
/ 1/ 2006

,
, :
6.2.
17 1999 N 178: ( :
, 1999, N 29, . 3699; 2004, N 35, . 3607) :
1. , ()
,
().
2. :
2 2004 . N 296 ( 7 2004 . N 6169),
2 2004 N 296 24 :
2004 . N 321 ( 29 2004 . N 6235),
31 2005 . N 245 ( 8 :
2005 . N 6485), 10 2005 . N 497
( 17 2005 . N 6913).
3. 1 2006 .
4. :
...

, ;
;

III.


; ,

48

;
; ,
;
; ; ;

, ;

, ;
;

; ;
;

, ;

;
;

;
;

+ +
+

IV.

V.

;
, ;

VI.

; ,
VII.

; ; ,
;
,

; ;
,

; ,

VIII.

IX.

49
/ 1/ 2006

, ;

50

; ;

, ;
()

, ;

, ; :
; :

; ,

, ;

, ;
()

()

XI.

;

;

,
II.

XIII. ,

; , ;

:1a

:1b

; ; ;
,

XIV. ,

V.

, ;

; , ;

51
/ 1/ 2006

52

; , ;
[ ];
;

, ; :

;
;

; ;

; ;
,

, ;

; ,

53

, ;

;
; ;

:2

:2a

VII.

, ;
; ;

VIII.

/ 1/ 2006

XVI.

() +

IX. ,

54

;
;

, ;

;
;

; ,


; ,

, ;

,
;

; ;

55
/ 1/ 2006

;
()

, ;

;
; ;

56

, ;


X.

; ,

I. , ,

; ,

[III]

; ;

[III]

+ +

VIII

IX

10000, 20000 ;

10000, 20000

()

XII. , 

, ;

+ +
+

; ;

; ;

; :
;

57
/ 1/ 2006

, ;

; ,

58

, ;

; ; ,
;
; :,

+ + +

; , ;

XIII. , 
, 
, ,
+

, ;

59
/ 1/ 2006

+ +

, ;

60

, ;

+ +

; ;

XIV. ,
,

; ;

; ;
;


; ;

+ +

; ;

;
;
();


; ;

; ; ;

; ,

()

( )

61
/ 1/ 2006

( )

: ( )

; ,

62

( )

()

; ;

V.

VI. ,

, (
);

; , ;

;
; ;

; ,
( );

XVII. ,

: ;

+ +

;
XVIII. ,


XXI.

; ,

63
/ 1/ 2006

64

; ()

+ + +

()

; ,

XXX.



XXXI.

+ +

(IgG + IgA + Ig)

+ + +

; ;

:3 (/:1.2/1:90%)

;
,

;
; ,

/ 1/ 2006

65


6th International Conference on
Priorities in Health Care
6

3rd Health Information Technology


(HIT) Summit
3

Europaediatrics

2022 2006 .
,
: Carolyn Farrell
: 1:416:946:0088
: 1:416:978:1911
E:Mail: carolyn.farrell@utoronto.ca

2527 2006 .
, ,
: Paul Tunnecliff
: 800:684:4549
: 760:418:8084
E:Mail:
registration@hcconferences.com

710 , 2006 .
,
:
17 Rue du Cendrier
PO Box 1726, CH:1211
Geneva 1, Switzerland
Tel: +41 22 908 0488
Fax: +41 22 732 2850
E:mail: europaediatrics@kenes.com

..
,



.
: (),
, .
: VEN:.
.
: , ,
.
:
,
,
;
: 119991, ,
, 2/62,
. (495) 134:15:19

66

:
. :
: :
: ::
(). ,

() [1].
,
, ,
, 9%.
, 2000 ., 50%
[2]. :
, ,
. :
. ,
:
. ,
: , ,
, :
. :
,
, :

.
1968 ., , , 1978 .

, , :
. :
.
,
[35].

,
:
[3, 6].
,
28.12.00 2510/43:29
, 18.03.00 2510/1684:
32 [7].

A.A. Stepanov
Scientific Center of Childrens Health, Russian Academy
of Medical Sciences, Moscow

Stages of the logbook system


introduction in a medical
institution

THE ARTICLE ADVANCES ARGUMENTS FOR AN ACTIVE INTRODUCTION OF


THE LOGBOOK SYSTEM IN MEDICAL INSTITUTIONS. THE MAIN ALGORITHM
OF THE LOGBOOK COMMITTEE ESTABLISHMENT, ITS ROLE IN THE WORK OF
A MEDICAL INSTITUTION, ITS MAIN FUNCTIONS AND POWERS ARE BRIEFLY
SET FORTH. THE ARTICLE PRESENTS ALGORITHMS FOR THE CREATION OF A
LOGBOOK LIST OF MEDICINAL REMEDIES AND CARRYING ON ABC AND VEN:
ANALYSES BY THE LOGBOOK:THERAPEUTIC COMMITTEE. THE MAIN
CRITERIA FOR THE INCLUSION OF A MEDICINE IN THE LOGBOOK ARE PRE:
SENTED.
KEY WORDS: ENSURING OF MEDICINAL REMEDIES PROVISION, LOG
BOOK COMMITTEE, LOGBOOK SYSTEM.

, . :

:

. , :

; :
, :
. :

:
; :
,
.
:, :
. :
,
,
:
.
, :
.
, , (:
), ( :
), ,
,
( 711 :
). :
, :
.

.
:
, . :


[1, 6, 13].
,
.
:
:
.

, :
.
:
.

.
,
.

.
,

.
,
,
.

.
.



.

67
/ 1/ 2006

:
,
, .
,
, :

,
[3, 6, 8].
:

(
,
..).
:
;
, :
. :
.. ,
:
(The United States Pharmaco:
peia Drug Information for Health Professionals),

(The Ameican Hospital Formulary Service Hand:
book). ,
:
.

,

. , :
, :
, :
. :
, , :
(:
+ ) :
:
. : :
:
,
:
.
, :
( 12 000 ), :
30300, :

:
[912].

.
,

, ,

,
, :
,
,
,
:, :
:
[6, 10].
:
::
().

, , ,

68

,
,
.

.

.
:
/. :
, , , :
, :
. :
:
,
, , :
. :
, :
. :
. , :
:
, . ,
, ,
.
:

:
() [1, 3, 5, 6]. :
.
. , :
, :
,
. :
,
, , :
:
, :
, :
, :
.
:
, :
, :
, ,
:
. :
, ,
, , :
.

. :
.
(, :
, , :
, .).
( ,
, .).
(, :
, , , , :
, .).
,
(,
, , :
, .).
. :
, , :
(,
, ..). :

:
.
:
, . :
,
, :
, ,
, :
.
:
,
.

. :
, , :

[5, 6, 8, 13].
:
.
:
:
.
, , 50


. :
[7, 13, 14]. :
, , :

. :
(
50 )
. :
. :
( )
50
(,
,
). ,
, ( ),
50
. ( ) :
:
.
:
.
: VEN:
. ABC:
(:
, :
). : 10:20% , 70:
80% ; : :
; : :
,
25% . ABC: :

. VEN: :
ABC:, :

(Vital), :
(Essential), (Non:essential).
(Vital) ,
,
(, )
.
(Essential)
, .

, ,
, .
.
.
:
.

: ,
.
, .
:

.
. :
:
.
:
.
,

.
. :
:
, .
. :
, , :

.. ,
,
,
.
:
.
. :
:
.
:
. :
/ :
.
.
:
.
( :
:
).
, :
.
, :
,
.

, , ,
:
.
:
.
:
:
. ,
,
,

.
:
, .
: :

69
/ 1/ 2006

(Non:essential) :
, :
; :
.

:
/ ,
, ,
[6, 7, 14].

.

, :
:
:
/
,
.
:
.
, .
,
. :
.

.
.
[6, 15].
, :
:
. :

, ,
.

.
ABC/VEN:

.
, ,

. :
, ,
.


. :

. :

,
.
:
. ,
.
:
.
(
).
(
).
C ( ).
(
).
( :
:
).

, ,

.

:
:
. :
:
.

70


1. .., ..
// :
1999. 1. . 815.
2. Feder G., Eccles M., Grol R., et al. Clinical guidelines: using clinical
guidelines // BMJ 1999. V. 7185. P. 72830.
3. ..
// . . 2000. 2. . 512.
4. .. :
// . . 1999. 1. . 37.
5. ICH Topic 6 Guideline for Good Clinical Practice // Good Clinical
Practice J. 1996. V. 3. 4 (Suppl.).
6. ., .., .. . :
: (, , :
) // 1999. .7 7. . 5 15.
7. 22.06.98. N86
( :
05.06.98) // :
, 26, 29.06.98, 3006.
8. The Declaration of Helsinki. Recommendations guiding medical
doctors in biomedical research involving human subjects, The World
Medical Association, 1964 (revised 1996).
9. .. : // .


, .
. :
:
[1, 2, 6, 8, 9].
:
,
.

1998. 3. . 3.
10. () :
( 17.04.1998
125) // . 1998. 6. . 148.
11. .. ,
// .
1996. 6. . 310.
12. Niederau C., Strohmeyer G., Heintges T., et al. Polyunsaturated
phosphatidyl:choline and interferon alpha for treatment of chronic
hepatitis B and C: a multi:center, randomized, double:blind, placebo:
controlled trial. Leich Study Group // Hepatogastroenterol 1998.
V. 21. P. 797804.
13. .., .. :
//
. . . 2000. 11. . 59.
14.
( ). ., 2000.
15. McWhirter J.P., Pennington C.R. Incidence and recognition of mal:
nutrition in hospital // BMJ. 1994. V. 9; 308(6934). P. 9458.
16. Lomas J. Words without action? The producion, dissemination
and impact of consensus recommendations // Ann Rev Public
Health 1991. V. 12. P. 4165.

.. 1, .. 2, .. 1, .. 1, .. 3
1 ,
2
3 : ,

72

:
:
().

.
, IGA, IGA , :
.
,
, :
.
: , , 
, .

:

,
:
. ,
:
.

: 142207, ,
. , . . 132,
. 8 (27)35:51:65

, :
, () 1025%
. 1824
[13]. 80% ,

[4].
:
. , 24%
, 28% :
[5]. :
,
.
, ,
.



(, GSK, ).

N.I. Kosiakova1, A.A. Liagina2, L.A. Andreeva1,


E.B. Grazhdankin1, A.A. Osnatch3
Hospital of the RAS Research Center, Pushino
Pediatric outpatient department of Serpukhov CRH
3
Sanitary:bacteriologic laboratory SSES, Serpukhov

The impact of the nasal spray


flutikazon on the local
immunity indices in allergic
rhinitis patients

THE IMPACT OF A TOPICAL GLUCOCORTICOID FLUTIKAZON ON THE DYNA:


MICS OF THE LOCAL IMMUNITY INDICES AND MICROBIOCENOSIS CONDI:
TION OF THE NASAL MUCOSA WAS STUDIED IN THE PATIENTS WITH THE
CONFIRMED DIAGNOSIS OF ALL THE YEAR ROUND ALLERGIC RHINITIS. IN A
YEAR ALL PATIENTS DEMONSTRATED A SUSTAINED CONTROL OF ALL THE
YEAR ROUND ALLERGIC RHINITIS SYMPTOMS. A STATISTICALLY SIGNIFI:
CANT INCREASE OF LYSOZYME, IGA, SECRETORY IGA, AND INTERFERON
CONCENTRATION IN THE NASAL AND MOUTH MUCOUS SECRETION AS WELL
AS THE DECREASE OF TUMOR NECROSIS FACTOR (TNF) CONCENTRATION
AND THE FREQUENCY OF YEAST LIKE FUNGI AND GRAM:NEGATIVE BACTE:
RIA GROWTH WERE REVEALED. THUS, LONG:TERM FLUTIKAZON THERAPY
HAS BROUGHT ABOUT A SUSTAINED REMISSION OF ALL THE YEAR ROUND
ALLERGIC RHINITIS CLINICAL MANIFESTATIONS AS WELL AS A SIGNIFICANT
IMPROVEMENT OF MICROBIOCENOSIS INDICES OF THE UPPER RESPIRATO:
RY MUCOUS MEMBRANES AND LOCAL IMMUNITY INDICES.
KEY WORDS: ALLERGIC RHINITIS, LOCAL IMMUNITY, MUCOUS MEM
BRANES MICROBIOCENOSIS, TOPICAL GLUCOCORTICOIDS.




268 (61,3%), :
31 (7%); 111
(25,4%) :

27 (6,1%)
.
, :
18 (4,1%), :
43 (9,8%), H1: II
92 (21%), H1: :
I 118 (27%), :
281 (64,3%),

14 (3,2%) 79 (18%) , H1::
38 (8,7%)
96 (21,9%) .

:
381 (87,2%).
31 (7%).
23 (5,2%), :
: 43 (9,8%). :
(, ,
, , )
5:
.
1: :
38% , 2:
69,2%; 26 17% , :
49 68,4% .


49,4% .
(
79,7% , 65,6%). :
S. aureus S. epidermidis 71,8
60,3% . (:
) 11,8% ,
12,6%, 5,6 4,9% :
, (P. aeruginosa E. coli)
3,2 4,5% . :
4,5% 8,2% ,
2,8%
4,9% .

. , :
1: 2:
3
. 1: :
49,7212,3
135,323,8 / ( 150,61 21,1/),
2: 48,9411,7 86,6215,6
/.
IgA sIgA (. 1). :
TNF
72,9% 1: 74,2% 2: .
TNF
1: (<0,05). :
IFN . 1 2.
:
96
(21,9%) 381 (87,2%) . :
18% .
2 :
.
:
, 17% (:
<0,005 ).

.
, IgA
1,8 , sIgA 2,7 . ,
:
. :
IFN :
.
IFN
:
Th1 :
IgE: . :
TNF :

:

73
/ 1/ 2006


437 :

[6]. 19,44,2 .
100
; 299 38. :
341
(78%). :
:
(49,3%), (22,7%),
(12,3%), (5,7%), (5,4%).

, , , :
: .
1: 276 ,
1
100 / H1:
II ; 2: 161 :
, H1:
, , :
, .
:
, :
[7], Ig (sIgA) :
(1: 108, 2:
104).
(4 C) 3000 / 30
. IgA sIgA
. :
(TNF)
(IFN) ( :
Escherichia coli)
(1: 108, 2: 104), :
(:)
, :
.
,
79 .
:
:
.
::
, , . :
:
[8].

StatSoft Statistica.

1.

IgA

IFN , /

sIgA

1: (n = 108)

0,0430,004

0,0270,009

25,22,8

47863

2: (n = 104)

0,0410,002

0,0290,006

23,73,4

47572

3: (n = 79)

0,10,02

0,0960,004

56,88,9

1010185

: <0,05
2.

74

IgA

IFN , /

sIgA

1: (n = 108)

0,0830,01

0,0780,006

49,24,8

1985112

2: (n = 104)

0,0440,006

0,0280,004

23,73,4

49474

3: (n = 79)

0,10,02

0,0960,004

56,88,9

1210185

: <0,01

[9].
, :
:

, :
:
.


1. .. // .
. 1999. 1. . 2324.
2.
: / . .. .
.: :, 2004. 48 .
3. .., .., .. :
:
//. . .
2002. 2. : . 1115.
4. Van Cauwenberge P., Bachert C., Bousquet J. et al. Consensus stati:
ment on the treatment of allergic rhinitis EAACI Position paper //Allergy.
2000. V. 55. P. 116134.

5. .. :
:
// . . . . , 2000.
6. ARIA. Allergic rhinitis and its impact on asthma. WHO initia:
tive, 2001.
7. .., ..
. , 1974.
8. .., .., .. .
. .:
, 1997.
9. .. /
. .: , 1998.

.



.

:
, ,
,
. :
, ,
,
,
,
.
.
:

. :
, , ( :
). ,
,
, .
:
(39,5 C ).
6 . :
. :
, ,

.
:
:
, :
. ,

, .

:
, , (
). ,
,
. :
, , :
.


:

. :
1 , :
:
.
, ,
;

. 2:3 ,
.

, :
. :
, .
:
, . :
, ,
:
. :
:
. , :
, :
.
:
. :
, .

:
, :
, :
, .
.
:
,
, :
. :

.



, , :
. ,

. :
:
.
.

75
/ 1/ 2006

:
( ).
, , :
. :
,
.
, :
. :
. ,

.

76

:
.
, :
.
:
.
:
.
:
. ,
,
.
2 , :
:
, ,
.
( CD),
. :
:
.

:
1. Word
Times, 12, 1,5 4. :
2,5 , 3,5 , 1,5
. :
. .
2. (
) :
.
3. : (
,
, );
() ();
, ,
(
);
, :
; (
150 ) : :
, ,
, :
; ; :
(,
, , ,
, ,
, , :mail).
.

4. : 15 ,
20 : , 7
.
: , (:
) , ,
().
:
, :
.
5.
, :
.

.
.
( 3),
, ,


. :
:
, :
.
:
, ,
, () () ,
( 0 ).
6.
: :
(), , :
;
. ,
:
:
. :

, ,
:

:
( ,
).
7.
: :
:
. ,
,
, : :

8.
:
. , :
, :

.
9. . :

,
.
. :
. species spp..
10. :
:
, ,
. Word.
Microsoft Graf Statistica.

(, )
; :
. , , :
.jpeg, .tif .eps,
300 ppi, :
100 . :
Word.
(: ) :
.
, :
,
( ).

, , .
11. :

.

:
.
25 , :
60. :
: , :
, , , :
;
:
( 4:, , :
. et al.), ,
(
Index Medicus MEDLINE),
, , , ;
:
, ,
.
,
.

1. .. . : .:
, 2000. 330 .
2. .. :
:
// :. 2001.
. 4, 6. . 5558.
3. .. :

: . . . . . :
, 2002. : 24 .
4. Kianfar H., Kimiagar M., Ghaffarpour M. Effect of daily
and intermittent iron supplementation on iron status of
high school girls // Int. J. Vitam. Nutr. Res. 2000. V.
70, N 4. P. 172177.
5. Bogen D.L., Duggan A.K., Dover G.J. et al. Screening for iron
deficiency anemia by dietary history in a high:risk population
// Pediatrics. 2000. V.105, N 6. . 12541259.

:
119991, , , . 2/62,
. (495) 967:15:66
:mail: pedpharm@nczd.ru

77
/ 1/ 2006

,
.



. ..

, :
1. ;
2. ,
, , ;
3. , ;
4. , , " "
;
5. , ;
6. , ;
7. , ;
8. ;
9. (
);
10. , .
: (495) 1341494

79
/ 1/ 2006

25 2005 . . .. :
.
..., ,
,
.

, , :
, 2003 .
:
.
:
:
, ;
,
;
.
5 :
1.
(. , :, .2/62).
. , , (.
(495) 1343083)
. ..., ,
(. (495) 1341494)
2.
:
(. , . , .5), . (495) 917:77:87, 917:48:31
. .., ,

3.
9 . .. (. , , .29), .
(495) 256:60:25, 259:96:75
. ..,
4. ,
, (. , .4), . (495) 438:21:00
. , ,
5.
( , .2/62, . (495) 967:14:14)
. ..., ,
, :
. "" .
72, 144, 216, 532 , :
, , , , .

2006 .
1.
:, , , ,




()

09.01.06 03.02.06
24
1,0 (144 )

2.
:, , ,




()

()

09.02.06 24.03.06
36
1,5 (216 )

3.
:, , , ,

80





()

27.03.06 21.04.06
26
1,0 (144 )

4.
:, , ,




()

()

24.04.06 07.06.06
36
1,5 (216 )

5.
:, , , ,




()

29.05.06 26.06.06
26
1,0 (144 )

6.
:, , ,




()

()

04.09.06 13.10.06
36
1,5 (216 )

7.
:, , , ,




()

16.10.06 10.11.06
26
1,0 (144 )

8.
:, , , ,




()

13.11.06 22.12.06
36
1,5 (216 )

Оценить